The US FDA has expanded the approval of evinacumab-dgnb (Evkeeza) to include patients aged 5 to 11 with homozygous familial hypercholesterolemia (HoFH). The drug, which inhibits lipoprotein lipase and endothelial lipase, showed a significant reduction in LDL-cholesterol levels in a study of 20 patients in this age group. Safety and efficacy data were similar to those in older patients with HoFH.
A otro idioma
del contenido fuente
www.medscape.com
Ideas clave extraídas de
by Steve Stiles a las www.medscape.com 03-22-2023
https://www.medscape.com/viewarticle/990016Consultas más profundas